• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>ISRN Urology >A Dual 5α-Reductase Inhibitor Dutasteride Caused Reductions in Vascular Density and Area in Benign Prostatic Hyperplasia
【2h】

A Dual 5α-Reductase Inhibitor Dutasteride Caused Reductions in Vascular Density and Area in Benign Prostatic Hyperplasia

机译：双重5α-还原酶抑制剂度他雄胺引起的前列腺增生症的血管密度和面积减少

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objectives. Dutasteride, a dual 5α-reductase inhibitor, is used to treat benign prostatic hyperplasia. Nevertheless, its histopathological effects on the morphometrics of blood vessels and glands are still controversial. The aim here was to assess the histopathological effects of dutasteride in cases of benign prostatic hyperplasia in a retrospective study. Methods. Patients with benign prostatic hyperplasia more than 40 cm3 in prostatic volume were administered 0.5 mg of dutasteride daily or left untreated prior to receiving a transurethral resection of the prostate. Images of sections stained with hematoxylin/eosin and with anti-CD31 antibody were analyzed. Results. In the dutasteride-treated group, the duration of administration was 16.3 ± 8.1 weeks. Artery/arteriole density and vein/venule density in benign prostatic tissue were both lower in the dutasteride-treated group than in the control group. The vein/venule area as a percentage of the whole area was also lower in the dutasteride-treated group, while the artery/arteriole area did not show a significant difference. Glandular/CD31-expressing vessel densities as well as glandular/CD31-expressing vessel areas were comparable between the two groups. Conclusions. Dutasteride reduced the artery/arteriole and vein/venule densities and the proportion of vein/venule area in the tissue of patients with benign prostatic hyperplasia.
机译：目标。双重5α-还原酶抑制剂度他雄胺用于治疗良性前列腺增生。然而，其对血管和腺体形态的组织病理学影响仍存在争议。本文的目的是在一项回顾性研究中评估度他雄胺在良性前列腺增生病例中的组织病理学影响。方法。前列腺体积超过40µcm 3 的良性前列腺增生患者每天接受0.5µmg的度他雄胺治疗，或在接受经尿道前列腺电切术之前不予治疗。分析了用苏木精/曙红和抗CD31抗体染色的切片的图像。结果。在度他雄胺治疗组中，给药时间为16.3±8.1周。在度他雄胺治疗组中，良性前列腺组织中的动脉/小动脉密度和静脉/小静脉密度均低于对照组。度他雄胺治疗组的静脉/小静脉面积占总面积的百分比也较低，而动脉/小动脉面积无明显差异。两组表达腺/ CD31的血管密度以及表达腺/ CD31的血管面积相当。结论。度他雄胺降低了良性前列腺增生患者的动脉/小动脉和静脉/小静脉的密度以及组织中静脉/小静脉的面积比例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号